Reasons to join
Based in Stockholm, Elypta have brought together some of the brightest scientific minds to tackle cancer in a totally new way. Joining Elypta is joining a mission-led business who are already having a huge impact with their groundbreaking multicancer early detection liquid biopsy technology.
The company have also sponsored the largest study ever focused on liquid biopsy-based kidney cancer diagnostics, AURORAX-0087A to test their platform. Since launching, the trial has seen Elypta's technology gain recognition at conferences such as the American Society of Clinical Oncology General Meeting and the European Association of Urology General Meeting.
The company have also had their findings published in publications such as PNAS and Cell Reports, further compounding their position as experts in the oncology diagnostic space.